Aminopeptidase A inhibitors are a class of antihypertensive drugs that work by inhibiting the conversion of angiotensin II to angiotensin III by the aminopeptidase A enzyme. The first medication in this class is firibastat.[1][2][3] It is hypothesized that the drugs may be more effective in overweight people and those of African descent.[4]
References
edit- ^ Blazek, Olivia; Bakris, George L (13 February 2023). "Novel Therapies on the Horizon of Hypertension Management". American Journal of Hypertension. 36 (2): 73–81. doi:10.1093/ajh/hpac111. PMID 36201204.
- ^ Ojha, Utkarsh; Ruddaraju, Sanjay; Sabapathy, Navukkarasu; Ravindran, Varun; Worapongsatitaya, Pitchaya; Haq, Jeesanul; Mohammed, Raihan; Patel, Vinod (2022). "Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension". American Journal of Cardiovascular Drugs. 22 (3): 271–285. doi:10.1007/s40256-021-00510-9. ISSN 1175-3277. PMC 8651502. PMID 34878631.
- ^ Khosla, Jagjit; Aronow, Wilbert S.; Frishman, William H. (January 2022). "Firibastat: An Oral First-in-Class Brain Aminopeptidase A Inhibitor for Systemic Hypertension". Cardiology in Review. 30 (1): 50–55. doi:10.1097/CRD.0000000000000360. PMID 33027067.
- ^ Lazartigues, Eric; Llorens-Cortes, Catherine; Danser, A. H. Jan (2023). "New Approaches Targeting the Renin-Angiotensin System: Inhibition of Brain Aminopeptidase A, ACE2 Ubiquitination, and Angiotensinogen". Canadian Journal of Cardiology. 39 (12): 1900–1912. doi:10.1016/j.cjca.2023.06.013. ISSN 0828-282X. PMID 37348757.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |